Bacteriophages in Infectious Diseases and Beyond-A Narrative Review
Overview
Affiliations
The discovery of antibiotics has revolutionized medicine and has changed medical practice, enabling successful fighting of infection. However, quickly after the start of the antibiotic era, therapeutics for infectious diseases started having limitations due to the development of antimicrobial resistance. Since the antibiotic pipeline has largely slowed down, with few new compounds being produced in the last decades and with most of them belonging to already-existing classes, the discovery of new ways to treat pathogens that are resistant to antibiotics is becoming an urgent need. To that end, bacteriophages (phages), which are already used in some countries in agriculture, aquaculture, food safety, and wastewater plant treatments, could be also used in clinical practice against bacterial pathogens. Their discovery one century ago was followed by some clinical studies that showed optimistic results that were limited, however, by some notable obstacles. However, the rise of antibiotics during the next decades left phage research in an inactive status. In the last decades, new studies on phages have shown encouraging results in animals. Hence, further studies in humans are needed to confirm their potential for effective and safe treatment in cases where there are few or no other viable therapeutic options. This study reviews the biology and applications of phages for medical and non-medical uses in a narrative manner.
Re-Emergence of Bacteriophages and Their Products as Antibacterial Agents: An Overview.
Kalia V, Patel S, Gong C, Lee J Int J Mol Sci. 2025; 26(4).
PMID: 40004222 PMC: 11855700. DOI: 10.3390/ijms26041755.
Bacteriophages: A Challenge for Antimicrobial Therapy.
Segundo-Arizmendi N, Arellano-Maciel D, Rivera-Ramirez A, Pina-Gonzalez A, Lopez-Leal G, Hernandez-Baltazar E Microorganisms. 2025; 13(1).
PMID: 39858868 PMC: 11767365. DOI: 10.3390/microorganisms13010100.
Phage therapy could be key to conquering persistent bacterial lung infections in children.
Sithu Shein A, Hongsing P, Khatib A, Phattharapornjaroen P, Miyanaga K, Cui L NPJ Antimicrob Resist. 2025; 2(1):31.
PMID: 39843534 PMC: 11721074. DOI: 10.1038/s44259-024-00045-4.
Considerations for prioritising clinical research using bacteriophage.
Edwards S, Tao Y, Elias R, Schooley R Essays Biochem. 2024; 68(5):679-686.
PMID: 39475266 PMC: 11652150. DOI: 10.1042/EBC20240013.
Moghtader F, Tabata Y, Karaoz E Gels. 2024; 10(8).
PMID: 39195022 PMC: 11353949. DOI: 10.3390/gels10080493.